Navigation Links
TransIT-siQUEST Transfection Reagent from Mirus Bio Corporation

ProductsTransIT-siQUEST Transfection Reagent from Mirus Bio Corporation
Company Mirus Bio Corporation
Item TransIT-siQUEST Transfection Reagent
Price $203.00
Description Cellular uptake of long double stranded RNA (dsRNA) has been shown to induce RNA interference in a diverse group of organisms as well as insect cells in culture. RNA interference leads to the inhibition of protein expression by utilizing sequence-specific, dsRNA-mediated destruction of the target messenger RNA (mRNA). Attempts to induce RNA interference using long dsRNA in mammalian cell lines have been met with limited success, due in part to the induction of the interferon response, which results in a general inhibition of protein synthesis. Recently, it has been shown that when short RNA duplexes are introduced into mammalian cells in culture, sequence-specific inhibition of target mRNA can be realized without introducing an interferon response. These short dsRNA, referred to as small interfering RNAs (siRNA), act catalytically at sub-molar ratios to cleave greater than 95% of the target mRNA in the cell. The RNA interference effect can be long-lasting and may be detectable after many cell divisions. These properties make siRNA extremely effective at inhibiting target gene expression.

Mirus Corporation, in recognition of these significant findings, has developed TransIT-siQUEST Transfection Reagent, which enables highly efficient siRNA transfection with significantly reduced levels of cell damage as compared to cationic-liposome based transfection reagents. Transfections are most effective when carried out in complete growth media, with no media change or serum addition required. TransIT-siQUEST Reagent efficiently delivers siRNA to a wide range of cell lines, promoting high levels of target gene expression knockdown. These unique features make the TransIT-siQUEST Transfection Reagent ideal for siRNA-mediated gene silencing studies. The TransIT-siQUEST Reagent is a complement to Mirus popular TransIT-TKO siRNA Transfection Reagent. Each unique formulation provides a distinct transfection profile for high efficiency, broad-spectrum siRNA delivery.

Info Mirus Bio CorporationMirus Bio Corporation
505 S. Rosa Rd.
Madison, WI 53719

Call Mirus Bio Corporation to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-866-438-6816
Customer Service: (888) 530-0801 or (608) 441-2852
Fax Number: (608) 441-2849
Web Site: http://www.mirusbio.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Label IT siRNA Tracker Fluorescein Kit with TransIT-siQUEST Reagent from Mirus Bio Corporation
2. Label IT siRNA Tracker CX Rhodamine Kit with TransIT-siQUEST Reagent from Mirus Bio Corporation
3. Label IT siRNA Tracker TM Rhodamine Kit with TransIT-siQUEST Reagent from Mirus Bio Corporation
4. Label IT siRNA Tracker Biotin Kit with TransIT-siQUEST Reagent from Mirus Bio Corporation
5. Label IT siRNA Tracker Cy3 Kit with TransIT-siQUEST Reagent from Mirus Bio Corporation
6. TransIT-siQUEST Transfection Reagent from Mirus Bio Corporation
7. GenomONE-Neo EX HVJ-E 4 vial(s) Transfection Reagents from Cosmo Bio Co., Ltd.
8. Label IT siRNA Tracker CX-Rhodamine Intracellular Localization Kit with TransIT-TKO siRNA Transfection Reagent from Mirus Bio Corporation
9. Label IT siRNA Tracker Intracellular Localization Kit with TransIT-TKO Transfection Reagent (Cy5 Labeling Kit) from Mirus Bio Corporation
10. Label IT siRNA Tracker Fluorescein Intracellular Localization Kit with TransIT-TKO siRNA Transfection Reagent from Mirus Bio Corporation
11. Label IT siRNA Tracker Biotin Intracellular Localization Kit with TransIT-TKO siRNA Transfection Reagent from Mirus Bio Corporation
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
...
...
Biology Products:
(Date:12/18/2018)... ... 2018 , ... Nativis, Inc. , a clinical stage ... announced the publication of an early feasibility study in CNS Oncology suggesting that ... publication of the study, An Early Feasibility Study of the Nativis Voyager® Device ...
(Date:12/14/2018)... ... December 14, 2018 , ... ... entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by the US Patent ... 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary Apte, ...
(Date:12/13/2018)... Va. (PRWEB) , ... December 12, 2018 , ... ... that Dr. Vinod Shah, one of the firm’s prominent Expert Consultants, was recently ... Award. The award recognizes leaders who are working in pharmaceutical science, technology, engineering, ...
Breaking Biology News(10 mins):
(Date:12/14/2018)... Alberta (PRWEB) , ... December 14, 2018 , ... ... Eye Machine Canada Inc., have been given the green light to immediately begin ... Macular Degeneration (AMD). , The medical devices bureau of Health Canada has granted ...
(Date:12/13/2018)... NEW YORK (PRWEB) , ... December 12, 2018 , ... ... introduce Styletto- their new sleek and slim hearing aid within its Vision and Hearing ... and hearing loss. , Studies show that despite continued efforts to destigmatize hearing ...
(Date:12/5/2018)... (PRWEB) , ... December 05, 2018 , ... Leading authority ... an all-new, how-to guide with his “The Referral Playbook: How to Increase Sales ... of the book proceeds will go to the Alzheimer’s Foundation of America (AFA). ...
(Date:12/5/2018)... and LONDON (PRWEB) , ... ... ... Group (ARG), an established North American full-service contract research organization (CRO), announced ... immediately, the transaction significantly strengthens ARG’s reach and experience in the management ...
Breaking Biology Technology: